Search results
Results from the WOW.Com Content Network
Sanofi-Aventis – Sanofi-Aventis Ltd; Sanofi Pasteur – Sanofi Pasteur MSD Ltd; Sanofi-Synthélabo – Sanofi-Aventis Ltd; Schering-Plough – Schering-Plough Ltd; Schwarz – Schwarz Pharma Ltd; Searle – Pfizer Ltd; Seqirus - was Novartis Vaccines Serono – Serono Pharmaceuticals Ltd; Servier – Servier Laboratories Ltd; Shire – Shire ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
This page was last edited on 8 December 2020, at 18:30 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Sanofi-Synthélabo merged with Aventis in 2004 to become Sanofi-Aventis. [10] On 17 March 2006, L'Oréal purchased cosmetics company The Body Shop for £562 million. [11] In May 2008, L'Oréal acquired YSL Beauté for $1.8 billion. [12] In January 2014, L'Oréal finalized the acquisition of major Chinese beauty brand Magic Holdings for $840 ...
Rhône-Poulenc (French pronunciation: [ʁon pulɛ̃k]) was a French chemical and pharmaceutical company founded in 1928.In 1999, it merged with Hoechst AG to form Aventis.As of 2015, the pharmaceutical operations of Rhône-Poulenc are part of Sanofi and the chemicals divisions are part of Solvay group and Bayer Crop Science.
Sanofi published readouts of three phase 3 trials of its tolebrutinib multiple sclerosis (MS) treatment. In the first study, the drug met its primary endpoint of delaying time to onset of ...
Chattem has announced it expects to take possession of the brands around January 2007. These mature brands will provide $150 million in additional revenue to Chattem per year. [citation needed] On December 21, 2009, Paris-based (France) Sanofi, the world's fourth largest drugmaker, said it was acquiring Chattem in a $1.9 billion cash deal.
Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase [1] used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects.